The anti-tumor effect was further enhanced when IL-2 was used to stimulate CD4+ T cells during EV production, resulting in an increased yield of CD4+ T cell-derived EVs and further strengthening the CD8+ T cell immunity. The gene discussed is CD8A; the disease is neoplasm.